About this program

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages. 

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 85% of them with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It has a restricted expression on normal tissues.

Lacutamab was granted orphan drug status in the European Union and in the United States for the treatment of CTCL. In January 2019, the US Food and Drug Administration (FDA) granted Innate Pharma Fast Track designation for lacutamab for the treatment of adult patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.

TELLOMAK, a global, multi-cohort, Phase II study evaluating the potential of lacutamab in different subtypes of T-cell lymphomas, has been initiated in the first half of 2019 (see clinical development).

Mechanism of action of lacutamab

Mechanism ok action IPH4102

The Phase II study TELLOMAK evaluating the potential of lacutamab in different subtypes of T-cell lymphomas (TCL) has been initiated in the first half of 2019.

TELLOMAK is a global, open-label, multi-cohort Phase II clinical trial conducted in the United States and Europe. In this clinical trial, lacutamab is being evaluated in patients with advanced t-cell lymphomas (TCL). TELLOMAK is expected to recruit up to 150 patients, with lacutamab evaluated:  

  • As a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab 
  • As a single agent in approximately 90 patients with mycosis fungoides (MF) who have received at least two systemic therapies 

In patients with MF, the study is designed to evaluate the benefit of lacutamab according to KIR3DL2 expression. The study comprises two cohorts in MF, testing lacutamab in KIR3DL2 expressing and non-expressing patients.  These cohorts follow a Simon 2-stage design that will terminate if treatment is considered futile. The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication. 

The primary endpoint of the trial is objective response rate. Key secondary measures include incidence of treatment emergent adverse events, quality of life, overall response rate, progression-free survival and overall survival. 


A Phase I trial has been conducted as an open label and multicenter study, performed in Europe (France, Netherlands, United Kingdom) and in the US. Participating institutions include several hospitals with internationally recognized expertise: the Saint-Louis Hospital (Paris, France), the MD Anderson Cancer Center (Houston, Texas), the Stanford University Medical Center (Stanford, CA), the Ohio State University (Columbus, OH), the Leiden University Medical Center (Leiden, Netherlands), and the Guy’s and St Thomas’ Hospital (London, United Kingdom).

  • The dose-escalation part has accrued 25 KIR3DL2-positive CTCL patients in 10 dose levels. The objective was to characterize lacutamab (IPH4102) safety profile, identify the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D); the dose escalation followed an accelerated 3+3 design. Results of the dose-escalation were presented at the EORTC CLTF meeting in October 2017
  • The cohort expansion enrolled 15 patients with Sézary Syndrome and 4 tMF receiving Lacutamab (IPH4102) at the RP2D until progression.

The primary objective of this trial was to evaluate the safety and tolerability of repeated administrations of single agent lacutamab in this patient population. The secondary objectives include assessment of the drug’s antitumor activity. Clinical endpoints include global objective response rate, response duration and progression-free survival. Exploratory analyses are aimed at identifying biomarkers of clinical activity.

In a presentation at EORTC CLTF meeting in September 2018 and updated results presented at the 2018 ASH Annual Meeting, lacutamab showed encouraging clinical activity, demonstrated by high response rate and long progression-free survival.


TCLF 2020: Anti-lymphoma activity of lacutamab, first-in-class anti-KIR3DL2 antibody, is augmented by PTCL chemotherapies453.88 KB
ICML 2019: TELLOMAK presentation702.17 KB
ICML 2019: KIR3DL2 is expressed in peripheral T-cell lymphomas and may be a therapeutic target521.62 KB
ICML 2019: KIR3DL2 contributes to delineate the Acute-type and is a therapeutic target in Adult T-cell leukemia/lymphoma674.14 KB
ASH 2018: IPH4102, an anti-KIR3DL2 mAb in refractory Sézary syndrome: results from a multicenter international phase 1 trial1.43 MB
EORTC CLTF 2018: IPH4102 results of the Phase 1 study in refractory CTCL863.07 KB
EORTC CLTF 2017: IPH4102 is safe and clinically active in advanced CTCL patients, results from the dose-escalation part664.71 KB
EORTC CLTF 2017: Biomarkers of pharmacological and clinical activity of IPH4102890.56 KB
ICML 2017: Dose-escalation safety, biomarker and clinical activity results (Phase I in relapsed/refractory CTCL)813.6 KB
ASH 2016: First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody1.49 MB
3WCCL: Presentation at the Scientific Session “Endpoints & Clinical Trials” with Pr Martine Bagot567.32 KB
Poster presented at the 3WCCL by Pr Martine Bagot731.18 KB
Poster presented at the 3WCCL by Hélène Sicard, Anne Marie-Cardine and Maxime Battistella628 KB
Poster presented at the 3WCCL by Maxime Battistella731.18 KB
Poster on IPH4102 presented at ASCO2016234.18 KB
Pr Martin Bagot presentation - Paris, Dec 2, 2015 - WARNING: some images may offend the sensibilities1.68 MB
Dr Youn H. Kim presentation, Key Opinion Leader luncheon to discuss Cutaneous T-cell Lymphoma2.52 MB
Pr Martin Bagot presentation at EORTC cutaneous lymphoma task force meeting - Torino sept. 2015 7.04 MB
Poster on IPH4102 presented at T-Cell Lymphoma Forum 2015160.66 KB
Poster on IPH4102 presented at T-Cell Lymphoma Forum 20142.65 MB
Poster on IPH4102 presented at AACR Annual Meeting 2013 1.06 MB